King Pharmaceuticals, Inc.
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 7, 2007 (December 6, 2007)
 
King Pharmaceuticals, Inc.
  
(Exact name of registrant as specified in charter)
         
Tennessee   001-15875   54-1684963
         
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (I.R.S. Employer
Identification No.)
     
501 Fifth Street, Bristol, Tennessee   37620
     
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: (423) 989-8000
 
N/A
  
(Former name or former address, if changed since last report)
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 8.01. Other Information
     On December 6, 2007, King Pharmaceuticals, Inc. and Pain Therapeutics, Inc. issued a joint press release reporting positive results of a Phase III study of RemoxyTM in patients with chronic pain. The press release is attached hereto as Exhibit 99.1.

 

 

     Item 9.01 Financial Statements and Exhibits.
  (d)   Exhibits
  99.1   Joint press release of King Pharmaceuticals, Inc. and Pain Therapeutics, Inc., issued December 6, 2007, regarding RemoxyTM.

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
Date: December 7, 2007  KING PHARMACEUTICALS, INC.
 		  
  By:   /s/ Joseph Squicciarino    
    Joseph Squicciarino   
    Chief Financial Officer   

 

 

         
EXHIBIT INDEX
         
Exhibit No.   Description
         
  99.1    
Joint press release of King Pharmaceuticals, Inc. and Pain Therapeutics, Inc., issued December 6, 2007, regarding RemoxyTM.